Menu
CHMP adopts a positive opinion acknowledging that Jardiance® reduces the risk of CV death
- In the EMPA-REG OUTCOME® trial Jardiance® reduced the risk of cardiovascular (CV) death by 38 percent vs placebo in patients with type 2 diabetes (T2D) and established CV disease when added to standard of care
- The Committee for Medicinal Products for Human Use (CHMP) recommends to update the existing label of Jardiance® (empagliflozin) for the treatment of adults with insufficiently controlled T2D
- This is the first time the CHMP supports the use of a diabetes treatment for its effect on both glycaemic control and CV events
Dans la même rubrique :
Mercredi 25 Décembre 2024 - 15:58 30 years of paired-up assistance: SW China's Xizang sees remarkable advances in healthcare |
Mardi 24 Décembre 2024 - 10:03 China contributes to global intellectual property rights governance |
Dimanche 10 Novembre 2024 - 09:52 Pourquoi la Monnaie Virtuelle est Essentielle pour l’Avenir des Systèmes Financiers Mondiaux |
